IPSC

Century Therapeutics, Inc. Common Stock

1.94

USD

IPSC Earnings Reports

Positive Surprise Ratio

IPSC beat 11 of 18 last estimates.

61%

Next Report

Date of Next Report

Mar 02, 2026

Estimate for Q4 25 (Revenue/ EPS)

-$0.26

Implied change from Q3 25 (Revenue/ EPS)

-18.75%

Implied change from Q4 24 (Revenue/ EPS)

-100.00%

-39.53%

Century Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, IPSC reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.34 USD, resulting in a 7.06% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -17.54% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.26 USD, with revenue projected to reach -- USD, implying an decrease of -18.75% EPS, and increase of 0.00% in Revenue from the last quarter.

FAQ

What were Century Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Century Therapeutics, Inc. Common Stock reported EPS of -$0.32, beating estimates by 7.06%, and revenue of $0.00, 0% as expectations.

How did the market react to Century Therapeutics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved down -17.54%, changed from $0.56 before the earnings release to $0.46 the day after.

When is Century Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 02, 2026.

What are the forecasts for Century Therapeutics, Inc. Common Stock's next earnings report?

Based on 7 analysts, Century Therapeutics, Inc. Common Stock is expected to report EPS of -$0.26 and revenue of -- for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.